Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma

Aurora kinase A (AURKA) has emerged as a drug target for glioblastoma (GBM). However, resistance to therapy remains a critical issue. By integration of transcriptome, chromatin immunoprecipitation sequencing (CHIP-seq), Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq), proteomic and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Trang T. T., Shang, Enyuan, Shu, Chang, Kim, Sungsoo, Mela, Angeliki, Humala, Nelson, Mahajan, Aayushi, Yang, Hee Won, Akman, Hasan Orhan, Quinzii, Catarina M., Zhang, Guoan, Westhoff, Mike-Andrew, Karpel-Massler, Georg, Bruce, Jeffrey N., Canoll, Peter, Siegelin, Markus D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410792/
https://www.ncbi.nlm.nih.gov/pubmed/34471141
http://dx.doi.org/10.1038/s41467-021-25501-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410792/
https://www.ncbi.nlm.nih.gov/pubmed/34471141
http://dx.doi.org/10.1038/s41467-021-25501-x

Ejemplares similares